EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Vector-Induced Humoral Responses After rVSVΔG-ZEBOV-GP Immunization Identify Vaccinated Individuals and Correlate With Ebola Virus Glycoprotein Antibodies

Prabha Chandrasekaran, Irina Maljkovic Berry iD, Viviane Callier, Scott M Anthony, Krystle Hensley, Jens H Kuhn iD, Kathryn Shaw-Saliba, Stephen B Kennedy, Mark Kieh, Sarah M Browne, Ian Crozier iD, Richard T Davey und 3 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae632 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Prabha Chandrasekaran und 14 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryla…. Hauptthemen laut MEDLINE: Antibodies, Viral, Ebola Vaccines, Ebolavirus, Hemorrhagic Fever, Ebola. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Liberian Ministry of Health, ODCDC CDC HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While vaccine antigen-induced antibodies are often used as proxies for vaccine efficacy, immune responses to vaccine vectors are less well-defined. We describe the kinetics of immunoglobulin (IgG) responses against the vector (vesicular stomatitis Indiana virus [VSIV]) nucleoprotein (N) and the inserted antigen (Ebola virus [EBOV]) glycoprotein (GP1,2) components of the rVSV-ZEBOV vaccine and evaluate their use as biomarkers to confirm self-reported vaccination status.

Methods

We selected 212 participants randomized to rVSV-ZEBOV (n = 107) or placebo (n = 105). Levels of IgG antibodies to EBOV GP1,2 or VSIV N were measured using an enzyme-linked immunosorbent assay and a newly developed single-molecule array (Simoa) immunoassay, respectively.

Results

Anti-EBOV GP1,2 and anti-VSIV N IgG were first detected 10-14 days postvaccination, further increased at 28 days, and remained stable through 360 days. Antibody titers were significantly correlated (P < 0.001) at 28 days (r = 0.47), 180 days (r = 0.45), and 360 days (r = 0.59). At 28 days, the area under the receiver operating characteristic curve (AUC) discriminated vaccinated from unvaccinated patients with high accuracy (AUC = 0.965 for anti-VSIV N IgG; AUC = 0.945 for anti-EBOV GP1,2 IgG [P < 0.001]).

Conclusions

We report a reliable assay to measure vector-induced humoral responses after rVSV-ZEBOV vaccination and demonstrate the assay's utility to confirm vaccination status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralEbola VaccinesEbolavirusHemorrhagic Fever, EbolaImmunity, HumoralGlycoproteinsHumansImmunoglobulin GFemaleAdultMaleYoung AdultMiddle AgedVaccinationVesiculovirusAdolescentEnzyme-Linked Immunosorbent Assay

Stichwörter der Autor:innen

EBOVEbola virusrVSV-ZEBOVrVSVΔG-ZEBOV-GPvaccine

Substanzen

Antibodies, ViralEbola VaccinesImmunoglobulin GGlycoproteins

Autor:innen und Institutionen

  • Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland.
  • Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • University of Liberia-Pacific Institute for Research & Evaluation (UL-PIRE) Africa Center, University of Liberia, Monrovia, Liberia.
  • Laboratory of Immunoregulation.
  • Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

ORCID-Profile: Irina Maljkovic Berry, Jens H Kuhn, Ian Crozier, H Clifford Lane, Dean A Follmann

Förderung

  • Liberian Ministry of Health
  • ODCDC CDC HHS
  • NCI NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIH/NIAID
  • Leidos Biomedical Research, Inc
  • Laulima Government Solutions, LLC
  • Clinical Monitoring Research Program Directorate

Zitieren

APA

Chandrasekaran, P., Berry, I. M., Callier, V., Anthony, S. M., Hensley, K., Kuhn, J. H., Shaw-Saliba, K., Kennedy, S. B., Kieh, M., Browne, S. M., Crozier, I., Davey, R. T., Lane, H. C., Hensley, L. E., & Follmann, D. A. (2025). Vector-Induced Humoral Responses After rVSVΔG-ZEBOV-GP Immunization Identify Vaccinated Individuals and Correlate With Ebola Virus Glycoprotein Antibodies. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae632

Vancouver

Chandrasekaran P, Berry IM, Callier V, Anthony SM, Hensley K, Kuhn JH, et al. Vector-Induced Humoral Responses After rVSVΔG-ZEBOV-GP Immunization Identify Vaccinated Individuals and Correlate With Ebola Virus Glycoprotein Antibodies. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae632

BibTeX
@article{Chandrasekaran2025,
  author = {Chandrasekaran, Prabha and Berry, Irina Maljkovic and Callier, Viviane and Anthony, Scott M and Hensley, Krystle and Kuhn, Jens H and Shaw-Saliba, Kathryn and Kennedy, Stephen B and Kieh, Mark and Browne, Sarah M and Crozier, Ian and Davey, Richard T and Lane, H Clifford and Hensley, Lisa E and Follmann, Dean A},
  title = {Vector-Induced Humoral Responses After rVSVΔG-ZEBOV-GP Immunization Identify Vaccinated Individuals and Correlate With Ebola Virus Glycoprotein Antibodies},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae632}
}
Kostenlos starten →